Skip to content
OpenLab

Antimicrobial Drugs: New Breakthroughs Provide Great Developments, But We Is Losing the Bigger Battle

During her time as head of the World Health Organization, a former leader famously stated that all of the “simple” antibiotics had long since been discovered. The point was that in addressing the pressing danger of drug-resistant bacterial infections, we would face difficulties to discover new medicines – or preserve the existing ones – without developing new ways of operating. This view was correct.

A Sluggish and Unprofitable Development Path

Since 2017, just sixteen antimicrobial agents have received widespread official clearance – mostly similar derivatives of drugs already in use and thus not expected to evade resistance for long. The creation of new ones is a lengthy and financially unattractive business, given that one-off medicines are less lucrative as those managing chronic conditions. The scientific outlook remains grim.

A Glimmer of Hope and a Novel Approach

However, the recent announcement of a pair of novel regulator-approved drugs against gonorrhoea is good news and, importantly, validates a new way of encouraging research. One of the recently approved medications, Zoliflodacin, is the product of a novel kind of partnership between a global health organization and a drug firm. The public health partnership supplied financial support and organised clinical trials to defray costs and navigate regulatory hurdles. This sort of support in advance helps steer the industry towards areas of greatest global need.

This model and another lauded revenue guarantee scheme – initiated to guarantee revenue to companies investing in certain antibiotics – constitute the strongest chance of maintaining a dripfeed of new drugs from the existing framework.

The Inevitable Challenge of Drug Resistance

But even hurrying the development of drugs currently in development isn't sufficient. The new drug is at times categorized as a novel type of antibiotic, meaning it targets a part of the infectious bacteria that existing treatments does, in principle forcing the bacterium to start from zero in developing a countermeasure to it. Researchers and doctors are grateful to have a new option for gonorrhea – which has resistant strains to every known antibiotic – but warn that future resistance to it is certain.

As has grown customary with new antibiotics, exists therefore an argument about whether it should be held in reserve, rationed to extremely drug-resistant cases only – confining its application to situations where high‑end lab testing is available. This kind of rational approach should be the global standard, but frequently cannot be deployed easily in many regions.

A Diminishing Pipeline of Discovery

More broadly, it is difficult to see where the stream of additional novel antimicrobials we require could possibly come from. The aforementioned comment nodded to the fact that searching the living world for biological compounds – as with penicillin – has had declining success. The application of AI has been mooted to accelerate the search, although a much-celebrated initial discovery identified in recent years has not yet progressed past preclinical studies. Synthetic drugs, which are largely or entirely lab-created, are continually in research, but often confront the fundamental rules of chemistry – the fact that we envision a molecule doesn't mean we can create it easily.

Moving Quickly to Stand Still

The dominant scientific evaluation is that when it comes to antibiotics, we must run very fast indeed just to remain in the current position. Prudent, internationally coordinated deployment is the sole method to maintain our therapeutic edge. Regrettably, the magnitude of future discoveries is going to seem meager in contrast to the curative bonanza of the previous century.

Written by

Mark Garcia

Education technology expert passionate about creating accessible learning environments and fostering digital literacy.

OpenLab

Type to search articles.